Understanding the Health Effect of a Bioactive Peptide From Egg: A Pilot Study

Last updated: March 12, 2026
Sponsor: University of Alberta
Overall Status: Active - Recruiting

Phase

1

Condition

Williams Syndrome

Obesity

Stress

Treatment

Egg White Powder

Clinical Study ID

NCT06555393
Pro00125956
  • Ages 18-70
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

Bioactive peptides derived from food proteins show potential for improving human health. One of such promising peptides is namely IRW made from egg white hydrolysate and composed of three peptides. This is a feasibility study to assess the acute effect of IRW in egg white hydrolysate for the management of high sugar and blood pressure.

Participants at high risk of type 2 diabetes (T2D) or having T2D will undergo 4 consecutive treatments of 1 day each (randomly), during which they will consume a standardized breakfast with a smoothie containing different protein powders. Each treatment will be separated by a minimum of 1-week.

Participants in the healthy control group will undergo 1 treatment only (one day).

Eligibility Criteria

Inclusion

Inclusion Criteria:

Healthy control group:

  • Men and women aged between 18 and 70 years living in Edmonton (or Edmontonarea/driving distance).

  • Normal weight (BMI below 25 kg/m2 or Asian population below 23 kg/m2 )

  • Waist circumference below the following ethnic specific cut offs: Canada / USA: <102cm men and <88 cm women; Europids, Middle-Eastern, Sub-Saharan African, andMediterranean: <94 cm men and <80 cm women; Asians, Japanese, South and CentralAmericans: <90 cm men and <80 cm women

  • Fasting glucose <5.6 mmol/L

  • HbA1c <5.6 %

  • Blood pressure <130/85 mmHg

  • Triglycerides <1.7 mmol/L

  • HDL-Cholesterol >1.03 mmol/L men and >1.29 mmol/L women

  • Body weight stable (within 3% fluctuation) for at least 6 months prior to the study

  • Individuals who have never smoke, have smoke less than 100 cigarettes in their lifeor who are long term quitter (quit smoking a year or more ago)

Individuals at risk of diabetes/having type 2 diabetes:

  • Men and women aged between 18 and 70 years living in Edmonton (or Edmontonarea/driving distance).

  • Overweight or obesity (BMI above 25 kg/m2 or Asian population above 23 kg/m2)

  • Waist circumference at or above the following ethnic specific cut offs: Canada /USA: ≥ 102 cm men and ≥ 88 cm women; Europids, Middle-Eastern, Sub-Saharan African,and Mediterranean: ≥ 94 cm men and ≥ 80 cm women; Asians, Japanese, South andCentral Americans: ≥ 90 cm men and ≥ 80 cm women

  • Fasting glucose ≥ 6.0 mmol/L

  • HbA1c ≥ 6.0 %

  • Body weight stable (within 3% fluctuation) for at least 6 months prior to the study

  • Individuals who have never smoke, have smoke less than 100 cigarettes in their lifeor who are long term quitter (quit smoking a year or more ago)

Exclusion

Exclusion Criteria:

  • Individuals with a previous history of CVD, renal disorder, monogenic dyslipidemia,with endocrine disorders other than T2D

  • Individuals taking chronic anti-inflammatory drugs (including aspirin,antihistamines, and omega-3 supplements)

  • Pregnant/lactating women

  • Individuals aged above 70 years

  • Smokers (current smokers: daily/occasional and those who have smoked more than 100cigarettes in their life)

  • Individuals with specific nutritional restrictions (e.g. vegetarianism excludingeggs from their diet, vegan or with egg allergy) will be excluded

  • Individuals with poorly controlled (HbA1c >12.0%) diabetes or taking exogenousinsulin will be excluded. Other anti-diabetic and lipid-lowering medications will bedocumented.

Study Design

Total Participants: 28
Treatment Group(s): 1
Primary Treatment: Egg White Powder
Phase: 1
Study Start date:
February 25, 2026
Estimated Completion Date:
October 31, 2026

Study Description

Bioactive peptides derived from food proteins show vast potential for improving human health, in addition to providing nutritional value. One of such promising peptides is a short tripeptide IRW (made of three amino acids, isoleucine-arginine-tryptophan), the first discovered peptide that can activate ACE2 (angiotensin converting enzyme 2) preclinically. ACE2 is best known as the entry receptor of some coronaviruses, including the pandemic's SARS-CoV-2, while the primary role of ACE2 is to provide protection on the cardiometabolic system. Therefore, activation of ACE2 is a novel strategy to mitigate cardiometabolic diseases. A decade-long collaborative research on IRW has established a large body of knowledge about IRW's health effects on hypertension, type-2 diabetes (T2D)/insulin resistance (IR), oxidation, and inflammation. To translate the knowledge for human applications, it is essential to investigate the bioavailability and efficacy of bioactive peptide IRW in egg white hydrolysate.

IRW is derived from ovotransferrin, which accounts for ~12% of total egg white protein. Egg white powder without a process of hydrolyzation will not liberate the IRW, therefore, this will be used as a negative control. However, it is too costly to prepare IRW from pure ovotransferrin for functional food applications. To reduce the cost of production, whole egg white could be used as the starting material. IRW can only be released by a combination of thermolysin and pepsin. If only thermolysin is applied, a pentapeptide IRWCT is formed; as pepsin is naturally secreted in the stomach, egg white hydrolysate will be prepared using thermolysin. It is expected that IRW will be released in vivo by the gastrically secreted pepsin.

This study is the first to translate a peptide ACE2 activator as a functional food for human applications against metabolic syndrome (MetS, hypertension, T2D/Insulin Resistance). A functional food containing IRW provides a dietary strategy for the mitigation of metabolic syndrome and presents a value-added opportunity for the Canadian egg industry.

Connect with a study center

  • University of Alberta

    Edmonton, Alberta T6G 2P5
    Canada

    Active - Recruiting

  • University of Alberta

    Edmonton 5946768, Alberta 5883102 T6G 2P5
    Canada

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.